EG-501 / Evergreen Therap - LARVOL DELTA

EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study (clinicaltrials.gov) - P2 | N=131 | Completed | Sponsor: Evergreen Therapeutics, Inc.

New P2 trial • Cognitive Disorders • Immunology • Inflammatory Arthritis • Lupus • Psychiatry • Systemic Lupus Erythematosus